GlassScriptPhysician profile
Holly Kane
NPI 1093408981
$5,273.95
in general payments reported to CMS, 2019-2025
26 companies · $3,273 in 2025
The $3,273 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,001 · 2025: $3,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,273.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,596.27 | 2024-2025 | Erleada, Rybrevant, Carvykti |
| Abbvie INC. | $655.50 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $543.24 | 2024-2025 | Orgovyx, Gemtesa |
| Ferring Pharmaceuticals INC. | $356.90 | 2024-2025 | Adstiladrin |
| Olympus America INC. | $248.35 | 2025 | Itind System |
| Bayer Healthcare Pharmaceuticals INC. | $225.21 | 2024-2025 | |
| Pfizer INC. | $221.21 | 2024-2025 | |
| Progenics Pharmaceuticals, INC. | $174.93 | 2024-2025 | |
| Axonics, INC. | $168.08 | 2024 | Axonics |
| Dendreon Pharmaceuticals LLC | $150.05 | 2024-2025 | Provenge |
| Teleflex LLC | $120.65 | 2024-2025 | Urolift, Barrigel |
| Urogen Pharma, INC. | $114.79 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $83.17 | 2024-2025 | Lynparza |
| Immunitybio, INC. | $78.25 | 2025 | |
| Procept Biorobotics Corporation | $73.80 | 2024-2025 | Aquabeam System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $68.27 | 2024 | Irrisept |
| Antares Pharma, INC. | $58.85 | 2024 | Xyosted |
| Astellas Pharma US INC | $57.96 | 2025 | Xtandi |
| Astrazeneca Pharmaceuticals LP | $51.77 | 2025 | Lynparza |
| Blue Earth Diagnostics | $48.16 | 2024 | |
| Endo USA, INC. | $47.07 | 2024-2025 | Xiaflex, Aveed |
| Novartis Pharmaceuticals Corporation | $38.13 | 2025 | |
| Myriad Genetic Laboratories, INC. | $34.47 | 2025 | Prolaris |
| Inspire Medical Systems, INC. | $24.67 | 2025 | Inspire |
| Boston Scientific Corporation | $20.77 | 2025 | Ams 800 Artificial Urinary Sphincter |
| Endo Pharmaceuticals INC. | $13.43 | 2024 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.